Regulatory Milestone and Clinical Indications The US Food and Drug Administration (FDA) has granted regulatory clearance for two new indications of Enhertu (fam-trastuzumab deruxtecan-nxki), a therapeutic agent discovered by Daiichi Sankyo and jointly managed with AstraZeneca. These newly added indications encompass the neoadjuvant (pre-surgical) and adjuvant (post-surgical) management of patients diagnosed with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer. The regulatory clearing is supported by clinical evidence generated from two distinct Phase III programs: the DESTINY-Breast11 and DESTINY-Breast05 trials. This milestone follows an administrative action in March 2026, during which the FDA granted Priority Review designation to the supplemental Biologics License Application rooted in the DESTINY-Breast05 data.
Therapeutic Application and Efficacy Framework
-
Clinical Settings: In the pre-surgical framework, Enhertu is authorized to precede a combination treatment of taxane, trastuzumab, and pertuzumab (THP) for individuals presenting with HER2-positive Stage II or Stage III breast cancer. In the post-surgical framework, the drug is approved for patients who present with residual invasive disease following prior taxane and trastuzumab-based regimens.
-
Safety Outcomes and Rationale: Oncologists note that while early-stage HER2-positive disease is highly curable, up to 1 in 4 patients still encounter disease recurrence, highlighting the necessity for advanced early intervention. Efficacy data from both the DESTINY-Breast11 and DESTINY-Breast05 clinical trials revealed no unforeseen safety anomalies or complications linked to Enhertu.
Commercial and Financial Framework Prior to these approvals, Enhertu had already secured therapeutic authorization in nearly 100 countries globally for the management of patients presenting with HER2-positive metastatic breast cancer. Following the execution of these two early-stage regulatory clearances in the United States, AstraZeneca will issue a milestone payment totaling $155 million to Daiichi Sankyo in accordance with their underlying collaboration terms.